As of Feb 24
| -0.05 / -1.63%|
The 3 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +132.56% increase from the last price of 3.01.
The current consensus among 4 polled investment analysts is to Hold stock in Merrimack Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.